Comparison · NCT02553317-9faae668
Caplacizumab vs Placebo: Number and Percentage of Subjects With TTP-Related Death, Recurrence of TTP, or a Major Thromboembolic Event During the Study Drug Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Caplacizumab vs Placebo: Number and Percentage of Subjects With TTP-Related Death, Recurrence of TTP, or a Major Thromboembolic Event During the Study Drug Treatment Period. Trial comparisons, record NCT02553317-9faae668. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02553317-9faae668
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.127 | 0.0681 | 0.224 | wilson | |
| Risk in group 2 | 0.493 | 0.382 | 0.605 | wilson | |
| Risk difference, group 1 minus group 2 | -0.366 | -0.493 | -0.219 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.257 | 0.134 | 0.494 | log | |
| Odds ratio, group 1 over group 2 | 0.149 | 0.0647 | 0.344 | log | |
| Number needed to treat, for one fewer participant with the outcome on Caplacizumab than on Placebo | 2.73 | 2.03 | 4.57 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Caplacizumab | Caplacizumab 10 mg once daily | 9 | 71 | OG000 |
| Group 2 | Placebo | Placebo once daily | 36 | 73 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number and Percentage of Subjects With TTP-Related Death, Recurrence of TTP, or a Major Thromboembolic Event During the Study Drug Treatment Period
- Description
Number and percentage of subjects with TTP-related death, a recurrence of TTP, or at least one treatment-emergent major thromboembolic event during the study drug treatment period (i.e., first key secondary endpoint).
- Time frame
The study drug treatment period, a median (min, max) of 36 (2, 82) days. For both treatment groups, only events that occurred prior to a switch to open-label caplacizumab were evaluated for this analysis.
- Population
- ITT Population (for the respective study period, i.e., overall treatment period)
Source ClinicalTrials.gov
Trial
- Title
- Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
- NCT number
- NCT02553317
- Phases
- PHASE3
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab, Placebo
- Lead sponsor
- Ablynx, a Sanofi company
- Results first posted
- 2019-05-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02553317?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02553317-9faae668